Long-term clinical profile of children with the low-penetrance R92Q mutation of the TNFRSF1A gene

Arthritis Rheum. 2011 Apr;63(4):1141-50. doi: 10.1002/art.30237.


Objective: To analyze the long-term impact of the R92Q mutation of TNFRSF1A in children with periodic fever, in comparison with children with tumor necrosis factor receptor-associated periodic syndrome (TRAPS) with TNFRSF1A structural mutations and children with periodic fever of unknown origin fulfilling the criteria for periodic fever, aphthosis, pharyngitis, and adenitis syndrome (PFAPA).

Methods: The extracellular region of TNFRSF1A was analyzed in 720 consecutive children with periodic fever, using denaturing high-performance liquid chromatography and DNA sequencing. Followup data on 11 pediatric patients with TNFRSF1A structural mutations (cysteine or T50M), 23 pediatric patients with an R92Q substitution, and 64 pediatric patients with PFAPA were collected during routine clinic visits. The 50-item Child Health Questionnaire was used to assess health-related quality of life (HRQOL).

Results: The frequency of typical TRAPS-related clinical manifestations was significantly lower and the impact of the disease on HRQOL was significantly reduced in patients with the R92Q mutation compared with TRAPS patients carrying structural mutations of TNFRSF1A. Followup data on 11 TRAPS patients with TNFRSF1A structural mutations (mean followup 7.9 years), 16 patients with theR92Q substitution (mean followup 7.3 years), and 64 patients with PFAPA (mean followup 5.2 years) were available. Patients with R92Q mutations and patients with PFAPA displayed a higher rate of self-resolution or amelioration of the fever episodes than did TRAPS patients with structural mutations.

Conclusion: Although some cases may progress to a more chronic disease course, the majority of children with an R92Q mutation of the TNFRSFA1 gene show a milder disease course than that in children with TNFRSFA1 structural mutations and have a high rate of spontaneous resolution and amelioration of the recurrent fever episodes.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Antirheumatic Agents / therapeutic use
  • Biological Therapy
  • Child
  • Child, Preschool
  • Familial Mediterranean Fever / drug therapy
  • Familial Mediterranean Fever / genetics*
  • Familial Mediterranean Fever / physiopathology
  • Female
  • Fever / drug therapy
  • Fever / genetics*
  • Fever / physiopathology
  • Follow-Up Studies
  • Genotype
  • Health Surveys
  • Humans
  • Infant
  • Interleukin 1 Receptor Antagonist Protein / therapeutic use
  • Longitudinal Studies
  • Lymphadenitis / drug therapy
  • Lymphadenitis / genetics*
  • Lymphadenitis / physiopathology
  • Male
  • Mutation / genetics*
  • Pharyngitis / drug therapy
  • Pharyngitis / genetics*
  • Pharyngitis / physiopathology
  • Quality of Life
  • Receptors, Tumor Necrosis Factor / physiology*
  • Receptors, Tumor Necrosis Factor, Type I / genetics*
  • Recurrence
  • Retrospective Studies
  • Steroids / therapeutic use
  • Syndrome


  • Antirheumatic Agents
  • Interleukin 1 Receptor Antagonist Protein
  • Receptors, Tumor Necrosis Factor
  • Receptors, Tumor Necrosis Factor, Type I
  • Steroids